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632elucidate the effect of cholesterol crystals on clinical
outcome.
In summary, cholesterol crystals within target
vessels requiring percutaneous coronary intervention
were observed in 39.6% of patients with stable coro-
nary artery disease. Lesions containing cholesterol
crystals exhibited FD-OCT–derived vulnerable plaque
features. These ﬁndings suggest an important asso-
ciation between cholesterol crystals and plaque
vulnerability in vivo.
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168–75.Does Body Adiposity
Better Predict Obesity-
Associated Cardiometabolic
Risk Than Body Mass Index?We read with great interest the paper by Chandra
et al. (1), which showed that baseline visceral adi-
posity, particularly retroperitoneal fat, was strongly
associated with incident hypertension in the Dallas
Heart Study.
To analyze the inﬂuence of adipose tissue distri-
bution on the development of hypertension, visceral
adipose tissue, subcutaneous adipose tissue, and
liver fat were quantiﬁed by magnetic resonance im-
aging and spectroscopy, lower body fat was measured
by dual-energy x-ray absorptiometry, and the inci-
dence of hypertension was observed after 7 years
of follow-up. The authors conclude that visceral
adiposity, rather than total adiposity, is more impor-
tant in the association of obesity with incident
hypertension.
Although precise and reproducible techniques
were used to measure the different fat depots, body
mass index (BMI) was used as a measure of total
adiposity. The utility of BMI for diagnosing obesity
has been shown to be very practical in population
studies. However, despite its wide use, BMI is only a
surrogate measure of body fat and does not provide
an accurate measurement of body composition (2).
Although most studies analyzing the inﬂuence of
obesity on the development of hypertension use BMI
as a proxy of adiposity, direct measurement of body
fat percentage may provide more interesting infor-
mation (3). Therefore, we believe that comparison of
the inﬂuence of every single fat depot with total
adiposity on incident hypertension would be more
precise if the authors used a more accurate measure
of total adiposity.
The authors performed dual-energy x-ray absorp-
tiometry, so they probably have data available
regarding actual total adiposity. Alternatively, they
could include the sum of the different fat depots
measured (visceral adipose tissue, subcutaneous ad-
ipose tissue, and lower body fat) as a more realistic
approximation of total adiposity than BMI. Although
visceral adipose tissue will surely remain the most
inﬂuential adipose depot on the development of
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633hypertension, a more precise inﬂuence of total adi-
posity may be obtained. This is important because
the cardiometabolic risk of many patients may be
underestimated when using BMI because it cannot
always properly discriminate the risk of chronic
disease at the individual level (4).
Data from the study by Chandra et al. (1) reinforce
the notion that focusing on body composition, rather
than BMI, when screening for obesity and overweight
may be helpful to better estimate cardiometabolic
risk in clinical practice (5).*Javier Gómez-Ambrosi, PhD
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crinol 2012;8:570–2.REPLY: Does Body Adiposity Better Predict
Obesity-Associated Cardiometabolic Risk
Than Body Mass Index?We thank Dr. Gómez-Ambrosi and colleagues for their
insights regarding our paper (1). We agree completely
with the notion that body mass index (BMI) has lim-
itations with regard to measuring adiposity, although
it certainly remains the most clinically used measure
of adiposity. For this reason, we believed it was an
important component to add to our multivariate
modeling.
As suggested, we did have access to data on
total body fat as measured by dual-energy x-ray ab-
sorptiometry; however, because this is not acommonly used measure of total adiposity, we did
not choose to use it in our multivariate modeling.
Nonetheless, total fat mass determined by dual-
energy x-ray absorptiometry was, like body mass
index, found to be highly associated with the devel-
opment of hypertension after adjusting for age,
baseline systolic blood pressure, sex, race/ethnicity,
history of smoking, and diabetes mellitus (relative
risk [RR]: 1.27; 95% conﬁdence interval [CI]: 1.14 to
1.41; p < 0.0001). However, as in the original analysis,
this association is attenuated when visceral adipose
tissue is included in the model (RR: 1.20; 95% CI: 0.89
to 1.62; p ¼ 0.24) while visceral adipose tissue re-
mains signiﬁcant (RR: 1.20; 95% CI: 1.04 to 1.39;
p ¼ 0.012). Thus, despite the addition of a more ac-
curate measure of total adipose mass, our conclusion
appears to remain the same, namely that visceral
adipose tissue is the adipose tissue depot most asso-
ciated with incident hypertension.Alvin Chandra, MD
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Studies of Culprit Lesions
Before MIWe read with interest the excellent editorial by Nar-
ula and Kovacic (1). This letter is to clarify issues in
the ﬁrst paragraph about our serial angiographic
studies of culprit lesions before myocardial infarction
(MI) (2,3).
We agree that the culprit occlusion causing an
MI contains usually substantial atherosclerosis with
superimposed thrombus. Furthermore, pathological
and cross-sectional intracoronary imaging shows that
the culprit usually produces a high-grade stenosis
(>90%). However, these observations are not incon-
sistent with our reports that the culprit frequently did
not contain a signiﬁcant angiographic stenosis when
evaluated before MI (2,3). The conclusions of our
